Quebec’s IntelGenx Receives Japanese Patent for VersaFilm

IntelGenx Technologies Corp. has received a decision to grant notice from the Japanese Patent Office (JPO) to issue a patent for Rizaport, an oral film dosage form for the delivery of rizatriptan benzoate for the treatment of acute migraines. Once the JPO’s administrative process is complete, the patent will provide intellectual property protection in Japan for the formulation of IntelGenx’s VersaFilm technology used in its Rizaport product until 2034. Based in Saint-Laurent, Quebec, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of oral films.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.